Aptose Biosciences Inc. (NASDAQ:APTO) Expected to Earn Q2 2024 Earnings of ($0.58) Per Share

Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) – Research analysts at HC Wainwright raised their Q2 2024 earnings estimates for shares of Aptose Biosciences in a note issued to investors on Tuesday, June 11th. HC Wainwright analyst J. Pantginis now anticipates that the biotechnology company will earn ($0.58) per share for the quarter, up from their prior estimate of ($0.94). HC Wainwright currently has a “Buy” rating and a $7.00 target price on the stock. The consensus estimate for Aptose Biosciences’ current full-year earnings is ($2.67) per share. HC Wainwright also issued estimates for Aptose Biosciences’ Q3 2024 earnings at ($0.64) EPS, Q4 2024 earnings at ($0.69) EPS and FY2024 earnings at ($2.62) EPS.

Several other analysts have also commented on APTO. Canaccord Genuity Group cut their target price on shares of Aptose Biosciences from $15.00 to $6.00 and set a “buy” rating for the company in a research note on Thursday, May 16th. StockNews.com began coverage on shares of Aptose Biosciences in a research note on Friday. They set a “hold” rating for the company. Finally, Piper Sandler reissued an “overweight” rating and set a $5.00 target price on shares of Aptose Biosciences in a research note on Wednesday, April 3rd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Aptose Biosciences currently has an average rating of “Moderate Buy” and an average target price of $14.83.

Aptose Biosciences Price Performance

APTO stock opened at $0.89 on Thursday. Aptose Biosciences has a 12 month low of $0.85 and a 12 month high of $6.00. The firm has a market cap of $16.10 million, a PE ratio of -0.14 and a beta of 1.39. The firm has a 50 day simple moving average of $1.16 and a 200 day simple moving average of $1.73.

Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last issued its quarterly earnings results on Tuesday, May 14th. The biotechnology company reported ($0.73) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.09.

Institutional Investors Weigh In On Aptose Biosciences

An institutional investor recently raised its position in Aptose Biosciences stock. Annandale Capital LLC lifted its position in Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) by 40.0% in the 3rd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 74,666 shares of the biotechnology company’s stock after acquiring an additional 21,334 shares during the quarter. Annandale Capital LLC owned approximately 0.99% of Aptose Biosciences worth $209,000 as of its most recent filing with the SEC. Hedge funds and other institutional investors own 26.62% of the company’s stock.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.